Xphyto Therapeutics Corp's Profile

Xphyto Therapeutics is accelerating the next-generation drug delivery, diagnostic and phytochemical investment opportunities: precision transdermal and oral dissolvable drug dosage forms; rapid, low-cost infectious disease and oral health screening tools; and validation of approved cannabinoid-based therapeutics focused on European markets.

Featured Posts

XPhyto Reports Successful Market Launch and Growing Demand for its 25-minute COVID-19 PCR Test COVID-ID Lab
AGORACOM Administrator
September 08
Xphyto Therapeutics Corp
Symbol
XPHY
Exchange
CSE
Shares
67,703,579 Sept. 2021
Industry
Technology & Medical
Website
Create a Post

Top Members

Xphyto Therapeutics Corp's Bulletin

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of an exclusive The Bell2Bell Podcast interview with Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During the interview with IBN’s Communications Director Jonathan Keim, Rogers offered an operational update, discussing the company’s most recent achievements and future plans. XPhyto Therapeutics recently obtained European approval and launched an effective 25-minute PCR (polymerase chain reaction) test for COVID-19, with an initial focus on the German market and several other initiatives underway. “This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that the company’s 25-minute COVID-19 RT-PCR test (Covid-ID Lab) sits between a rapid antigen test and a centralized automated high-throughput PCR, offering diagnostic quality, fast results and ease of administration at point of care, whether that is a medical clinic, a pharmacy, a cruise ship turnover or airport, or any mobile testing center. Following the CE-IVD approval (European certification) of the test, the company is focused on commercialization in Germany, with a footprint in Austria, while also conducting a number of other initiatives. One such initiative is in Israel, where XPhyto is looking to obtain approval for its Covid-ID Lab, as that market could also serve as a launching point to a number of Middle Eastern countries. “There is certainly no shortage of opportunities, particularly close to Europe,” Rogers added. XPhyto’s CEO then discussed the recent addition of Manfred Buchberger as Head of Corporate Development at wholly owned German subsidiary XP Diagnostics GmbH. Buchberger was formerly global head of sales and CEO of a major European diagnostics and analytics company, which he helped grow from a couple of million dollars a year to nearly $1 billion in revenue. “He is an expert in his field, and we’re very fortunate to have him on board,” Rogers explained. “He is leading our product launch and sales initiatives and we’re just very happy to have him involved and looking to expand his role in the near future.” When asked to comment on how XPhyto became a $150-million-dollar company listed on three different exchanges, Rogers underlined that his organization has evolved significantly and is now something of a technology accelerator/incubator making early-stage investments and always looking for low-cost or value-driven investment opportunities, with scalability platform technologies and largely driven by its scientific network. That means easier access to opportunities before anyone else, as well as securing further opportunities by virtue of the company’s success so far, he said. “I think we’ve demonstrated now that we can take a product to market in a very short period of time, we have a pipeline of diagnostics products, we have a drug formulation business, as well as a psychotropic or psychedelic medicines program,” Rogers explained. “So, a lot of exciting opportunities, certainly timely, and the fact that we can move very quickly and allocate capital very effectively and quickly is helping our growth plans.” Detailing its drug formulation program, Rogers discussed the acquisition of Vektor Pharma TF, a thin film drug formulator based in Germany. “They have about 20+ scientists working there, and their focus is both transdermal drug delivery systems and oral dissolvables; for example, sublingual dissolvable strips, buccal dissolvable formulas,” he said. Rogers added that XPhyto and Vektor have four pilot studies planned for this year and have already completed a first one in Q1 successfully for their lead product, a Parkinson’s transdermal drug delivery system for Rotigotine. He explained that this is a generic product, and that they have a number of hybrid generic products in the pipeline as well. “This goes back to our investment strategy – Vektor really has scalable opportunities, so for relatively low costs in the generic or hybrid generic space, we can develop a drug formula using existing API, possibly an existing drug platform such as transdermal, or maybe a hybrid situation where we’ve reformulated in a new delivery system,” Rogers added. “But, in any case, it’s low cost to market, we don’t have to establish safety or efficacy of this particular compound or focus on the drug formulation side.” The XPhyto CEO concluded the interview reiterating that this was an exciting time for the company, with multiple opportunities ahead, and underlined that he was looking forward to making more announcements on that front later this year. Join InvestorBrandNetwork’s Jonathan Keim and Hugh Rogers, CEO and director of XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), to learn more about XPhyto’s 25-minute COVID-19 RT-PCR test distribution plans, its expert management team and innovative drug formulation program. To hear the whole interview and subscribe for future episodes, visit: https://podcast.bell2bell.com The latest installment of The Bell2Bell Podcast continues to reinforce InvestorBrandNetwork’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine About InvestorBrandNetworkThe InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.For more information on IBN, visit https://www.InvestorBrandNetwork.com.
Research and development lab set up, preliminary mescaline synthesis complete Modified synthesis process developed, mescaline batches manufactured Development of analytical methods and validation, GMP standard operating procedures and manufacturing scale-up underway XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that its GMP mescaline synthesis program is on schedule with the completion of initial production batches. The industrial scale manufacture of pharmaceutical grade psychedelic compounds, including mescaline and psilocybin, is an important part of XPhyto's psychedelic medicine program and will provide a foundation for its drug formulation and clinical validation work. Since launching its mescaline synthesis program in early 2021, XPhyto is pleased to be on schedule having completed lab set up, preliminary synthesis, modified synthesis, and initial batch production. The Company is currently focused on the scale up of production capability and the development of analytical methods and validation. Development of standard operating procedures (SOP) for GMP certification of the synthesis process is also underway. "With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto's psychedelic medicine program is progressing on schedule. As the manufacturing programs advance, we look forward to focusing our expertise on psychedelic drug formulation," said Hugh Rogers, CEO & Director. "We see a significant market opportunity in the production of pharmaceutical grade psychedelics followed by the standardization of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use." Psychedelic compounds have emerged as a new class of drugs with the potential to improve the treatment of mental health related medical conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring psychedelic compound found in certain cacti, such as peyote, and as recently reported in the publication ACS Pharmacology and Translational Science, naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. Of the respondents reporting histories of depression, anxiety, post-traumatic stress disorder (PTSD), and alcohol and drug use disorders (AUD and DUD), most (68-86%) reported subjective improvement following their most memorable mescaline experience1. Further to the Company's press release dated February 3, 2021, its GMP mescaline production program is carried out under contract by Applied Pharmaceutical Innovations ("API"), a not-for-profit institution at the University of Alberta created to support translational drug development for industry and innovators. All intellectual property is retained by XPhyto. On November 3, 2020, the Company announced an agreement with a leading German university for the exclusive development of a proprietary biotechnology process for the industrial manufacture of pharmaceutical grade psilocybin. The Company will provide further information and updates in due course. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. XPhyto Therapeutics Corp.Hugh Rogers, CEO and Director Investor Inquiries:Mr. Knox HendersonT: 604-551-2360E: info@xphyto.com Media Inquiries:MC Services AGJulia Hofmann, Andreas JungferT: +49 89 210 228 0E: xphyto@mc-services.com